1. Home
  2. MRK vs NVO Comparison

MRK vs NVO Comparison

Compare MRK & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Merck & Company Inc. (new)

MRK

Merck & Company Inc. (new)

N/A

Current Price

$133.91

Market Cap

329.7B

Sector

Health Care

ML Signal

N/A

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

N/A

Current Price

$37.97

Market Cap

199.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MRK
NVO
Founded
2000
1923
Country
United States
Denmark
Employees
75000
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
329.7B
199.4B
IPO Year
1997
2001

Fundamental Metrics

Financial Performance
Metric
MRK
NVO
Price
$133.91
$37.97
Analyst Decision
Buy
Hold
Analyst Count
28
13
Target Price
★ $161.53
$45.73
AVG Volume (30 Days)
7.1M
★ 10.1M
Earning Date
10-29-2026
11-04-2026
Dividend Yield
2.65%
★ 3.30%
EPS Growth
★ 8.01
N/A
EPS
N/A
★ N/A
Revenue
★ $65,011,000,000.00
N/A
Revenue This Year
$3.43
$0.47
Revenue Next Year
$3.27
$0.96
P/E Ratio
★ N/A
$13.60
Revenue Growth
★ 1.31
N/A
52 Week Low
$96.06
$35.12
52 Week High
$157.00
$64.16

Technical Indicators

Market Signals
Indicator
MRK
NVO
Relative Strength Index (RSI) 33.72 38.84
Support Level $111.89 $37.61
Resistance Level $154.15 $39.64
Average True Range (ATR) 4.15 1.00
MACD -1.61 -0.23
Stochastic Oscillator 11.39 2.31

Price Performance

Historical Comparison
MRK
NVO

About MRK Merck & Company Inc. (new)

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: